You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
Merck
McKinsey
Colorcon

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,964,550

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,964,550
Title:At-home blood pregnancy test kit
Abstract: Disclosed is an at-home blood pregnancy test kit that can identify the presence of hCG in a blood sample to detect pregnancy in female mammals. The present kit includes a housing having a sample strip that is in fluid communication with a sample pad for holding a blood sample, a test pad, and a conjugate pad. The housing further includes a test window and a push button for releasing a reagent that can react with hCG. The reagent and the test pad include antibodies that can bind with hCG antigens to detect presence of the same. The test window is adapted to display a symbol that indicates a negative pregnancy test result in the absence of hCG, or display a symbol that indicates a positive pregnancy test result in the presence of hCG.
Inventor(s): Sanders; Melinda (Rochester, IN)
Assignee:
Application Number:14/615,628
Patent Claims:1. A blood pregnancy test kit, comprising: a housing comprising an interior volume, an upper end having a semi-circular cut-out extending radially inward, and a lower end, the lower end comprising a push button; the semi-circular cut-out defining an opening providing access to the interior volume of the housing; the push button comprising an interior volume and a seal, wherein the interior volume of the push button contains a reagent, the reagent comprising a first antibody that binds with human chorionic gonadotropin (hCG) antigen, wherein pressing the push button causes the seal to break, thereby releasing the reagent; a sample strip positioned in the opening defined by the semi-circular cut-out, the sample strip comprising a first end extending outward from the opening and a second end extending into the interior volume of the housing; a sample pad disposed in the interior volume, the sample pad in contact with the second end of the sample strip and in fluid communication with the sample strip; wherein the sample strip is composed of a porous material configured to transport a blood sample to the sample pad; wherein the sample pad is composed of a sponge-like material; a test pad disposed in the interior volume of the housing, the test pad in contact with the sample pad and in fluid communication with the sample pad; the test pad comprising a test portion having a second antibody that binds hCG antigen; the housing further comprising a second cut-out portion positioned above the test pad, such that the test pad is viewable from an exterior of the housing; a conjugate pad disposed in the interior volume of the housing, the conjugate pad in contact with the test pad and in fluid communication with the test pad; wherein the conjugate pad is positioned directly subjacent the push button, such that the reagent is released onto the conjugate pad upon the push button being pressed; wherein the test pad is positioned between the sample pad and the conjugate pad, wherein the sample pad, the test pad, and the conjugate pad are coplanar relative to each other and define a contiguous surface; wherein the sample pad is configured to transport the blood sample to the test pad; wherein the conjugate pad is configured to transport the reagent to the test pad; wherein following transport of each of the reagent and the blood sample to the test pad, each of the reagent and the sample combine on the test pad to form a blood-reagent mixture and each of the first and second antibody bind with hCG antigen when hCG antigen is present in the sample.

2. The blood pregnancy test kit of claim 1, wherein the test pad comprises a control portion having an indicator to display a marking when the blood-reagent mixture contacts the control portion.

3. The blood pregnancy kit of claim 1, wherein the test pad exhibits a first symbol in order to indicate a positive pregnancy test when the presence of hCG antigen in the sample is above a predetermined threshold value; and wherein the test pad exhibits a second symbol in order to indicate a negative pregnancy test when the presence of hCG antigen in the sample is below the predetermined threshold value.

4. The blood pregnancy test kit of claim 3, wherein the first symbol is a plus sign and the second symbol is a minus sign.

Details for Patent 9,964,550

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 004 1975-06-26   Start Trial 2034-02-18 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 006 1975-06-26   Start Trial 2034-02-18 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 007 1975-06-26   Start Trial 2034-02-18 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 009 1975-06-26   Start Trial 2034-02-18 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 010 1975-06-26   Start Trial 2034-02-18 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 011 1975-06-26   Start Trial 2034-02-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
Dow
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.